panobinostat + cytarabine + mitoxantrone

This is a **triple combination regimen** consisting of panobinostat, cytarabine (also known as Ara-C), and mitoxantrone, developed for use as salvage therapy primarily in **relapsed or refractory acute myeloid leukemia (AML)**. - **Panobinostat** is an oral pan-deacetylase (pan-DAC) inhibitor that increases acetylation of proteins involved in cell cycle regulation, gene transcription, angiogenesis, and tumor cell survival. - **Cytarabine** is a nucleoside analog antimetabolite that inhibits DNA synthesis by acting as a cytosine analog. - **Mitoxantrone** is an anthracenedione antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks. Panobinostat has been shown **preclinically to potentiate the cytotoxic activity** of both cytarabine and mitoxantrone, and this combination has demonstrated some anti-leukemic activity in clinical studies. Clinical trials in relapsed/refractory AML patients established the maximum tolerated dose (MTD) of panobinostat in this combination to be 50 mg taken orally three times weekly, in combination with fixed-dose cytarabine and mitoxantrone administered intravenously. The regimen was generally tolerable, with gastrointestinal and hematologic toxicities being prominent adverse events. However, meaningful improvement in remission rates and long-term survival remains unproven, and response rates in heavily pretreated patients have not indicated strong efficacy[1][2][5][6][7].